Albert A. Antolin
Albert A. Antolin
Sir Henry Wellcome PostDoctoral Fellow, The Institute of Cancer Research, UK
Verified email at icr.ac.uk - Homepage
TitleCited byYear
In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities
C Rubio-Perez, D Tamborero, MP Schroeder, AA Antolín, J Deu-Pons, ...
Cancer cell 27 (3), 382-396, 2015
1712015
Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology
AA Antolín, X Jalencas, J Yélamos, J Mestres
ACS chemical biology 7 (12), 1962-1967, 2012
532012
canSAR: an updated cancer research and drug discovery knowledgebase
JE Tym, C Mitsopoulos, EA Coker, P Razaz, AC Schierz, AA Antolin, ...
Nucleic acids research 44 (D1), D938-D943, 2015
412015
Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors
AA Antolín, J Mestres
Oncotarget 5 (10), 3023, 2014
282014
Distant polypharmacology among MLP chemical probes
AA Antolín, J Mestres
ACS chemical biology 10 (2), 395-400, 2014
172014
Polypharmacology in precision oncology: current applications and future prospects
A A Antolin, P Workman, J Mestres, B Al-Lazikani
Current pharmaceutical design 22 (46), 6935-6945, 2016
142016
Exploring the effect of PARP-1 flexibility in docking studies
AA Antolin, A Carotti, R Nuti, A Hakkaya, E Camaioni, J Mestres, ...
Journal of Molecular Graphics and Modelling 45, 192-201, 2013
122013
Objective, quantitative, data-driven assessment of chemical probes
AA Antolin, JE Tym, A Komianou, I Collins, P Workman, B Al-Lazikani
Cell chemical biology 25 (2), 194-205. e5, 2018
62018
In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals novel targeting opportunities
C Rubio-Perez, D Tamborero, MP Schroeder, AA Antolin, J Deu-Pons, ...
Cancer Research 75 (15 Supplement), 2983-2983, 2015
22015
Knowledge base for nuclear receptor drug discovery
AA Antolín, J Mestres
Therapeutic Targets: Modulation, Inhibition, and Activation, 309-326, 2012
22012
canSAR: update to the cancer translational research and drug discovery knowledgebase
EA Coker, C Mitsopoulos, JE Tym, A Komianou, C Kannas, P Di Micco, ...
Nucleic acids research, 2018
2018
Dual Inhibitors of PARPs and ROCKs
AA Antolín, J Mestres
ACS omega 3 (10), 12707-12712, 2018
2018
Abstract B096: canSAR, a cancer research and drug discovery knowledgebase
EA Coker, P Di Micco, JE Tym, C Mitsopoulos, A Komianou, AA Antolin, ...
Molecular Cancer Therapeutics 17 (1 Supplement), B096-B096, 2018
2018
Abstract A024: Probe Miner: objective, quantitative, data-driven assessment of chemical probes for target validation
AA Antolin, JE Tym, A Komianou, I Collins, P Workman, B Al-Lazikani
Molecular Cancer Therapeutics 17 (1 Supplement), A024-A024, 2018
2018
The Polypharmacology Gap Between Chemical Biology and Drug Discovery
AA Antolin, J Mestres
Computational Tools for Chemical Biology 3, 349, 2017
2017
IDENTIFICATION OF DIFFERENTIAL KINASE OFFTARGETS AMONG CLINICAL PARP INHIBITORS: NEW OPPORTUNITIES FOR PRECISION ONCOLOGY?
AA Antolin, J Mestres, P Workman, B Al-Lazikani
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 121, 65-66, 2017
2017
The Impact of Distant Polypharmacology in the Chemical Biology of PARPs
AA Antolín, J Mestres
Concepts and Case Studies in Chemical Biology, 309-322, 2014
2014
The system can't perform the operation now. Try again later.
Articles 1–17